



14 May 2020

Sydney, Australia

## Noxopharm ASCO Abstracts Live

---

### Highlights

- Release of Veyonda® data to major oncology conference in late-May
- Important confirmation that idronoxil (Veyonda®) in pre-clinical studies promotes infiltration of tumours by immune cells, a major prerequisite in the current goal of converting COLD tumours into HOT tumours
- Final DARRT-1 and updated LuPIN trial data confirming safety and signs of durable efficacy of Veyonda® therapy in heavily pre-treated end-stage prostate cancer

**Sydney, 14 May 2020:** Noxopharm (ASX: NOX) today announces the publication by The American Society of Clinical Oncology (ASCO) of three abstracts concerning Veyonda® ahead of the Society's virtual 2020 Annual Meeting from 29 to 31 May 2020.

Abstract #1 presents important new information on the immuno-oncology properties of idronoxil, the active compound in Veyonda®. Collaborators at Hong Kong University studying the immuno-oncology properties of idronoxil, have confirmed in pre-clinical studies that idronoxil promotes infiltration of tumours by immune cells. They have shown this in nasopharyngeal carcinoma cells, a rare cancer in Western countries, but endemic in Southern China and South-East Asia generally and a major cause of death in young Cantonese Chinese.<sup>1</sup>

Commenting on this abstract, **Dr Olivier Laczka, Director of Drug Discovery and Research**, said: "The anti-cancer responses we are seeing in end-stage prostate cancer patients with Veyonda®, including abscopal responses, have led us to speculate that one of its effects is restoring immune function to tumours. Most tumours in many forms of cancer appear to survive and grow by actively expelling immune cells, leading to them being referred to as cold tumours. Finding a way to turn cold tumours into hot tumours and repopulating the tumours with immune cells has emerged as a high priority in cancer research. Unfortunately to date this effort has had little success."

"This study shows that idronoxil, at least in the laboratory, is able to deliver this important function. Combine that observation with our clinical observations in the DARRT and LuPIN programs and we have growing confidence that Veyonda® is a drug capable of doing this in the clinic."

Abstracts # 2 and 3 relate to clinical data of Veyonda® in the DARRT and LuPIN programs. These two abstracts are considerably abridged versions of the presentations that will be published online by ASCO during the meeting. Noxopharm will provide a summary of the more complete data immediately following publication by ASCO during the Meeting in late-May.



The DARRT-1 abstract summarises the final results of the now completed DARRT-1 study, previously announced on 2<sup>nd</sup> December 2019, but now being presented to a global scientific audience for the first time. The abstract describes the safety results and highlights the major efficacy endpoints of the study. Specifically, the RECIST evaluation at 6 months showed that out of 15 evaluable patients, 10 patients had stable disease or better and had maintained this response for at least 3 months.

The LuPIN abstract reports on all three patient cohorts for the first time. There have been no dose-limiting toxicities observed, which is a major success and underlines the very good safety profile of Veyonda<sup>®</sup>. The poster will provide further updated data of the ongoing trial.

Details of the three abstracts are below.

#### **DARRT-1 Poster Presentation**

Poster Title: Phase I study of a novel S1P inhibitor, NOX66, in combination with radiotherapy in patients with metastatic castration-resistant prostate cancer.  
Presenter: Professor Paul de Souza  
Abstract: <https://meetinglibrary.asco.org/record/187730/abstract>

#### **LuPIN Poster Presentation**

Poster Title: Updated results of a Phase I/II prospective dose escalation trial evaluating safety and efficacy of combination <sup>177</sup>Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).  
Presenter: Associate Professor Louise Emmett  
Abstract: <https://meetinglibrary.asco.org/record/188003/abstract>

---

#### **Nasopharyngeal Carcinoma Preclinical Study Abstract**

Online abstract title: Effect of idronoxil combined with cisplatin on refractory immune responses in nasopharyngeal carcinoma.  
Authors: N-W Kam, VH-F Lee et al.  
Abstract: <https://meetinglibrary.asco.org/record/189715/abstract>

#### References

1. *Titcomb CP (2001). High incidence of nasopharyngeal carcinoma in Asia. J Insur Med 33: 235-238*

#### **About ASCO**

The American Society of Clinical Oncology (ASCO) is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. The virtual annual meeting this year will be held from May 29-31, 2020.

**About Noxopharm**

Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda<sup>®</sup> and is the major shareholder in the non-oncology drug development company, Nyrada Inc. (ASX:NYR).

[www.noxopharm.com](http://www.noxopharm.com)

**Investor & Corporate Enquiries:**

Prue Kelly

M: 0459 022 445

E: [info@noxopharm.com](mailto:info@noxopharm.com)

**Company Secretary:**

David Franks

T: +61 2 8072 1400

E: [David.Franks@automicgroup.com.au](mailto:David.Franks@automicgroup.com.au)

**Media Enquiries:**

Catherine Strong

Citadel-MAGNUS

T: 02 8234 0111

E: [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

*Graham Kelly, CEO and Chairman of Noxopharm, has approved the release of this document to the market.*

**Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.